Regeneron Pharmaceuticals (REGN) Change in Accured Expenses (2009 - 2026)

Regeneron Pharmaceuticals' Change in Accured Expenses history runs 18 years deep, the most recent figure standing at $107.7 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 150.3% year-over-year to $107.7 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 157.88% increase from a year earlier, with the FY2025 full-year figure at $736.8 million, changed 0.23% from the prior year.
• Change in Accured Expenses improved to $107.7 million in Q1 2026 per REGN's latest filing, from -$24.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $759.2 million in Q3 2025 and bottomed at -$250.4 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $110.5 million (2024), against an average of $120.0 million.
• Across the five-year window, Change in Accured Expenses plunged 621.61% in 2022 and surged 460.95% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at $347.6 million in 2022, then sank by 139.9% to -$138.7 million in 2023, then surged by 262.65% to $225.6 million in 2024, then slumped by 110.95% to -$24.7 million in 2025, then soared by 536.03% to $107.7 million in 2026.
• Per Business Quant, the three latest REGN Change in Accured Expenses figures stand at $107.7 million (Q1 2026), -$24.7 million (Q4 2025), and $759.2 million (Q3 2025).